Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
American Society of Hematology (ASH)
Biotech
45 days later, BioCryst abandons another drug, citing competition
BioCryst trimmed its pipeline to two drugs last month. Fast forward 45 days, and BCX9930 is headed to the garbage can too.
Annalee Armstrong
Dec 15, 2022 10:29am
ASH: Regeneron lymphoma med scores but safety muffles excitement
Dec 12, 2022 5:30pm
ASH: Senti Bio's CAR-NK therapy shows promise in leukemia
Dec 9, 2021 9:05am
Allogene CAR-T posts 60% response rate in competitive BCMA field
Dec 7, 2020 8:03am
Regeneron's bispecific banishes 2 kinds of lymphoma
Dec 6, 2020 3:00pm
Kura chalks another one up for menin inhibitors in leukemia
Dec 5, 2020 12:30pm
